IP Library Granted Patent US 8,735,450
Granted Patent B2
US 8,735,450 · App. 13/266,122 · Granted May 27, 2014

Formulation of diclofenac

Inventors: Aaron Dodd (Centennial Park, AU); Felix Meiser (Mount Claremont, AU); Marck Norret (Darlington, AU); Adrian Russell (Rivervale, AU); H William Bosch (Bryn Mawr, PA)
Assignee: Iceutica Pty Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,735,450
App. No.
13/266,122
Granted
May 27, 2014
Kind
B2
Abstract

The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.

Claims (20)

1. A method for producing a composition comprising nanoparticles of diclofenac acid, comprising:

dry milling a composition comprising diclofenac acid, lactose and sodium lauryl sulfate in a mill containing a plurality of milling bodies for a time period sufficient to produce a composition comprising nanoparticles of diclofenac acid having a median particle size on a particle volume basis between 1,000 nm and 25 nm; and processing the composition comprising nanoparticles of diclofenac acid into a unit dosage pharmaceutical composition containing 18 mg of diclofenac acid, wherein the unit dosage pharmaceutical composition, when tested in vitro by USP Apparatus I (Basket) method of U.S. Pharmacopoeia at 100 rpm at 37 °C. in 900 ml of 0.05% sodium lauryl sulfate in citric acid solution buffered to pH 5.75, has a dissolution rate of diclofenac acid such that at least 91%, by weight, is released by 45 minutes.

2. The method of claim 1 wherein the processing comprises combining the composition comprising nanoparticles of diclofenac acid with at least one pharmaceutically acceptable excipient or carrier.

3. The method of claim 2 wherein the processing comprises combining the composition comprising nanoparticles of diclofenac acid with microcrystalline cellulose, croscarmellose sodium, and sodium stearyl fumarate.

4. The method of claim 1 wherein the unit dosage pharmaceutical composition comprises a hard gelatin capsule.

5. The method of claim 1 or 4 wherein the unit dosage pharmaceutical composition has a dissolution rate of diclofenac acid such that at least 91%, by weight, is released by 30 minutes.

6. The method of claim 1 or 4 wherein the unit dosage pharmaceutical composition has a dissolution rate of diclofenac acid such that at least 91%, by weight, is released by 15 minutes.

7. The method of claim 1 or 4 wherein the unit dosage pharmaceutical composition has a dissolution rate of diclofenac acid such that at least 94%, by weight, is released by 45 minutes.

8. The method of claim 1 or 4 wherein the unit dosage pharmaceutical composition has a dissolution rate of diclofenac acid such that at least 94%, by weight, is released by 30 minutes.

9. The method of claim 1 wherein the unit dosage pharmaceutical composition is a filled capsule.

10. A method for producing a composition comprising nanoparticles of diclofenac acid, comprising:

dry milling a composition comprising diclofenac acid, lactose and sodium lauryl sulfate in a mill containing a plurality of milling bodies for a time period sufficient to produce a composition comprising nanoparticles of diclofenac acid having a median particle size on a particle volume basis between 1,000 nm and 25 nm; and processing the composition comprising nanoparticles of diclofenac acid into a unit dosage pharmaceutical composition containing 35 mg of diclofenac acid, wherein the unit dosage pharmaceutical composition, when tested in vitro by USP Apparatus I (Basket) method of U.S. Pharmacopoeia at 100 rpm at 37 °C. in 900 ml of 0.05% sodium lauryl sulfate in citric acid solution buffered to pH 5.75, has a dissolution rate of diclofenac acid such that at least 82%, by weight, is released by 45 minutes.

11. The method of claim 10 wherein the processing comprises combining the composition comprising nanoparticles of diclofenac acid with at least one pharmaceutically acceptable excipient or carrier.

12. The method of claim 11 wherein the processing comprises combining the composition comprising nanoparticles of diclofenac acid with microcrystalline cellulose, crosscarmellose sodium, and sodium stearyl fumarate.

13. The method of claim 10 wherein the unit dosage pharmaceutical composition comprises a hard gelatin capsule.

14. The method of claim 10 or 13 wherein the unit dosage pharmaceutical composition has a dissolution rate of diclofenac acid such that at least 82%, by weight, is released by 30 minutes.

15. The method of claim 10 or 13 wherein the unit dosage pharmaceutical composition has a dissolution rate of diclofenac acid such that at least 82%, by weight, is released by 15 minutes.

16. The method of claim 10 or 13 wherein the unit dosage pharmaceutical composition has a dissolution rate of diclofenac acid such that at least 95%, by weight, is released by 45 minutes.

17. The method of claim 10 or 13 wherein the unit dosage pharmaceutical composition has a dissolution rate of diclofenac acid such that at least 95%, by weight, is released by 30 minutes.

18. The method of claim 10 wherein the unit dosage pharmaceutical composition is a filled capsule.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2013
From: MEISER, FELIX; NORRET, MARCK; RUSSELL, ADRIAN
To: ICEUTICA PTY LTD.
Reel/Frame 030912/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2013
From: DODD, AARON
To: ICEUTICA PTY LTD.
Reel/Frame 030912/0290 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2013
From: BOSCH, H. WILLIAM
To: ICEUTICA PTY LTD.
Reel/Frame 030912/0407 →
Priority Claims (1)
AU 2009901748 · Apr 24, 2009 · national
Continuity (2)
Provisional Application 61172291 · Apr 24, 2009
Related Publication 20120135047A1 · May 31, 2012